IceCure ProSense Cryoablation Evaluated in Treatment for Breast Cancer

April 22, 2025—IceCure Medical Ltd. announced findings from three investigator-initiated studies of the company’s ProSense system for the cryoablation treatment of breast cancer. The data were delivered in two scientific sessions and one poster presentation at ECIO 2025, the European Conference on Interventional Oncology held April 13-16 in Rotterdam, the Netherlands.

First, Sophie M. Wooldrik, MD, presented “Review of the indications and results of the different techniques of thermal ablation on breast tumors; the treatment of breast cancer with percutaneous thermal ablation—THERMAC: An open-label phase 2 screening trial.” The study enrolled 41 women and compared cryoablation to radiofrequency ablation and microwave ablation.

As summarized in the company’s press release, the investigators concluded that only cryoablation met the requirement to proceed to a phase 3 study, with an efficacy rate of 94%, a complication rate of 0%, and a 100% treatment tolerance. Additionally, the study found that 94% of patients were very satisfied or satisfied with the thermal ablation technique, and 95% of patients stated they would choose thermal ablation versus breast-conserving surgery.

Next, Professor Thomas J. Vogl, MD, presented “CT-guided cryoablation of primary breast cancer: Evaluation of efficacy and safety,” which was composed of 45 patients with 56 tumors (mean diameter 1.6 ± 0.7 cm). The study concluded that cryoablation is a safe and effective treatment for primary breast cancer. The mean overall progression-free survival was 2.9 years (95% CI, 2.3-3.6), reported IceCure.

Finally, the poster presentation, “Nonsurgical treatment of breast cancer: a comparison of outcomes between cryoablation with hormonal therapy versus cryoablation alone and hormonal therapy alone in patients not eligible for surgery,” showed that cryoablation with hormonal therapy reduced tumor size and residual disease more effectively than hormonal therapy or cryoablation alone, making it a promising option for patients not eligible for surgery, stated the company.

This study was composed of 64 patients who were not suitable for surgery. A total of 73 tumors (mean, 14.8 mm) were treated. Tumor size reduction was greatest in the cryoablation with hormone therapy (HT) group (94%, mean reduction of 15.4 mm), followed by cryoablation only (82%, mean reduction of 9.7 mm), and then HT only (43%, mean reduction of 4.6 mm), stated IceCure’s press release.